Authors
Stefanie M Werhahn, Christian Becker, Meinhard Mende, Helge Haarmann, Kathleen Nolte, Ulrich Laufs, Samira Zeynalova, Markus Loeffler, Nikolaos Dagres, Daniela Husser, Marcus Doerr, Stefan Gross, Stephan B Felix, Astrid Petersmann, Christoph Herrmann‐Lingen, Lutz Binder, Martin Scherer, Gerd Hasenfuss, Burkert Pieske, Frank Edelmann, Rolf Wachter
Publication date
2022/2
Journal
ESC heart failure
Volume
9
Issue
1
Pages
100-109
Description
Aims
Heart failure (HF) and atrial fibrillation (AF) frequently coexist and are both associated with increased levels of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). It is known that AF impairs the diagnostic accuracy of NT‐proBNP for HF. The aim of the present study was to compare the diagnostic and predictive accuracy of NT‐proBNP for HF and AF in stable outpatients with cardiovascular risk factors.
Methods and results
Data were obtained from the DIAST‐CHF trial, a prospective cohort study that recruited individuals with cardiovascular risk factors and followed them up for 12 years. Data were validated in three independent population‐based cohorts using the same inclusion/exclusion criteria: LIFE‐Adult (n = 2869), SHIP (n = 2013), and SHIP‐TREND (n = 2408). Serum levels of NT‐proBNP were taken once at baseline. The DIAST‐CHF study enrolled 1727 study participants (47.7% female, mean …
Total citations
Scholar articles
SM Werhahn, C Becker, M Mende, H Haarmann… - ESC heart failure, 2022